NCT05610202View on ClinicalTrials.gov

Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects

PHASE1UnknownINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions
Hematologic Malignancy
Interventions
DRUG

TQB3702 tablets

TQB3702 tablets are selective BTK inhibitors.

Trial Locations (2)

250117

The Cancer Hospital Affiliated to Shandong First Medical University, Jinan

330006

The First Affiliated Hospital of Nanchang University, Nanchang

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY